United-Guardian, Inc. Stock price
Is United-Guardian, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🧮 Calculation
📊 P/E (TTM) = Based on earnings from the last 12 months (Trailing Twelve Months):🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🧮 Calculation
Market Cap = $32.76m | Revenue (TTM) = $11.21m
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🧮 Calculation
Enterprise Value = $23.17m | Revenue (TTM) = $11.21m
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Dividend per Share (DPS)
📈 What is it?
Dividend per Share shows how much cash a company pays out to shareholders for each share they own – usually on an annual or quarterly basis.
🧮 How is it calculated?
🏛️ Why is it important?
DPS is the absolute value of the payout per share – crucial for income-focused investors and dividend strategies.
🧮 Calculation
🎯 What does this mean for investors?
- A stable or growing DPS often signals a strong, shareholder-friendly business.
- DPS alone doesn’t tell you how attractive the payout is – the stock price also matters (→ see Dividend Yield).
- Long-term dividend growth is often a hallmark of high-quality companies – like the dividend aristocrats.
📘 Dividend Yield
📈 What is it?
Dividend yield shows how large a company’s dividend is in relation to its current share price.
🧮 How is it calculated?
🏛️ Why is it important?
It allows investors to compare dividend payouts across stocks, regardless of price or payout size.
🧮 Calculation
🎯 What does this mean for investors?
- A stable yield can reflect reliable distributions.
- Comparing 1Y and 5Y yield shows whether dividend growth keeps pace with stock price appreciation.
- A low yield isn’t always negative – it can signal strong past performance or growth focus.
📘 Dividend Growth
📈 What is it?
Dividend growth shows how much a company has increased its dividend per share over time.
🧮 How is it calculated?
5Y: Compound Annual Growth Rate (CAGR)
🏛️ Why is it important?
Consistently rising dividends are often a sign of financial strength and shareholder orientation – especially relevant for long-term investors.
🧮 Calculation
🎯 What does this mean for investors?
- Stable dividend growth is a sign of sustainable earning power.
- High dividend growth can significantly boost your total return:
- If a company pays $1 in dividends and increases it by 15% annually over 5 years, you’ll receive $2 per share in year 5 – twice as much as at the start!
📘 Payout Ratio
📈 What is it?
The payout ratio shows what percentage of a company’s earnings (per share) is distributed to shareholders as dividends.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess whether the dividend is sustainable – especially in relation to the company’s profitability.
🧮 Calculation
🎯 What does this mean for investors?
- A low payout ratio means the company retains more earnings for reinvestment – typical for growth companies.
- A moderate payout (e.g. 25–50%) indicates a healthy balance between returns and reinvestment.
- High payout ratios may seem attractive but can carry risk if earnings decline.
📘 Consecutive Dividend Increases
📈 What is it?
This metric shows how many consecutive years a company has raised its dividend per share – without any cuts or pauses.
🧮 How is it calculated?
(Special dividends are not considered.)
🏛️ Why is it important?
A long track record of increases reflects financial strength, consistency, and shareholder commitment.
🎯 What does this mean for investors?
- A long dividend increase streak builds confidence – especially in volatile markets.
- Such companies are seen as reliable and income-friendly investments.
- The longer the streak, the stronger the company’s dividend discipline.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🧮 Calculation
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🧮 Calculation
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🧮 Calculation
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🧮 Calculation
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🧮 Calculation
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🧮 Calculation
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🧮 Calculation
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🧮 Calculation
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🧮 Calculation
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🧮 Calculation
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🧮 Calculation
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
United-Guardian, Inc. Events
Past Events
|
MAY
13
Guardian, Inc. - Shareholder/Analyst Call - United-Guardian, Inc.
5 months ago
|
StocksGuide Free
United-Guardian, Inc. — Guardian, Inc. - Shareholder/Analyst Call - United-Guardian, Inc.
1. Management Discussion
Okay. Good morning. I'm Donna Vigilante, President of United Guardian, and I hereby call to order the Annual Meeting of the Stockholders of United Guardian, Inc., which is being held by video conference this 13th day of May 2026. Andrea Young, Secretary of the corporation, is present and pursuant to the bylaws of the corporation will act as Secretary of the meeting.
Good morning. I present a copy of the notice of this meeting, which has been sent to each stockholder of record together with proof of mailing of such notice. I ask that this notice and the affidavit of mailing be filed on the records of the corporation.
I move that the notice of this meeting, together with the affidavit of mailing be filed in the records of the corporation. I second the motion.
All those in favor of the motion, say aye.
[Voting]
Aye.
Aye.
All those opposed, say no.
[Voting]
The motion is carried and the Secretary is directed to file the notice and affidavit of mailing with the record of the corporation.
We have a list of stockholders of the corporation as of March 30, 2026, the record date fixed by the Board of Directors for those stockholders entitled to notice of this meeting. This list has been prepared and certified by Continental Stock Transfer and Trust Company, registrar of the corporation. May I ask for a motion that the list be filed in the records of the corporation.
I move that the list be filed in the records of the corporation.
I second the motion.
All favoring the motion, say aye.
[Voting]
Aye.
All opposed, say no.
[Voting]
The motion is carried and the Secretary is directed to file this list of stockholders with the records of the corporation. I will now call for nominations for inspection of election.
Sorry, I nominate Andrea Young and Barbara Ricardo to be inspectors of election.
I second the motion.
Are there any further nominations? If not, I declare nominations closed. All those in favor of the election of Andrea Young and Barbara Ricardo as inspectors of election, please say aye.
[Voting]
Aye
Aye
All those opposed say no.
[Voting]
Andrea Young and Barbara Ricardo have been elected inspectors of election. Will the inspectors please sign the oath of office and turn it into the company at the end of this meeting. The inspectors of election have reported the holders of a total of 3,637,702 shares are present by proxy. The total number of shares present constitutes a quorum and represents 79% of the 4,594,319 shares outstanding.
The meeting may now proceed to business. Copies of the company's annual report for fiscal year 2025 have been mailed to all stockholders of record. In view of this fact, I ask for a motion dispensing with the reading of the report and directing the secretary to file the report with the records of the corporation.
I move that the reading of the annual report be dispensed with and that it be filed with the records of the corporation.
I second the motion.
All those in favor of the motion, say aye.
[Voting]
Aye.
All those opposed, say no.
[Voting]
The motion is carried and the Secretary is directed to file the annual report with the records of the corporation. The next order of business is the election of directors of the corporation for the coming year. I ask for nominations for the office of director.
I nominate the following as directors of the corporation for the ensuing year: Ken Globus, Lawrence F. Maietta, S. Ari Papoulias, Arthur M. Dresner, Andrew A. Boccone, Catherine Kolinski and Donna Vigilante.
I second the nominations.
Are there any further nominations? I ask for a motion to close the nominations.
I move that the nominations be closed.
I second the motion.
All those in favor, say aye.
[Voting]
Aye.
All opposed, say no.
[Voting]
The motion is carried. The proxies contain the following proposals: to elect 7 directors to serve until the next annual meeting; to approve the holding of an advisory vote every 1, 2 or 3 years on the compensation paid to the company's named executive officers; to approve on an advisory basis, the actual compensation paid to the company's named executive officers; to ratify the appointment of Grassi & Company, CPAs P.C. as the independent public accountants of the company for the fiscal year ending December 31, 2026.
Since there is no voting taking place at the meeting today, I can report that based on the information provided to the company by Continental Stock Transfer and Trust Company, the company's stock transfer agent, the voting results were as follows: On the proposal to elect 7 directors to serve until the next annual meeting. Ken Globus received 2,300,653 votes for, 385,055 votes against, 6,960 abstentions, 945,034 broker nonvotes. Lawrence F. Maietta received 2,269,236 votes for, 324,776 votes against, 98,656 abstentions, 945,034 broker nonvotes. Arthur M. Dresner received 2,532,497 votes for, 61,445 votes against, 98,726 abstentions, 945,034 broker nonvotes.
Andrew A. Boccone, 2,498,527 votes for, 95,415 votes against, 98,726 abstentions, 945,034 broker nonvotes. S. Ari Papoulias, 2,503,521 votes for, 90,421 votes against, 98,726 abstentions, 945,034 broker nonvotes. Catherine Kolinski, 2,525,859 votes for, 71,585 votes against, 5,224 abstentions, 945,034 broker nonvotes. Donna Vigilante, 2,319,320 votes for, 356,944 votes against, 7,404 abstentions, 945,034 broker nonvotes.
On the proposal to approve the holding of a vote every 1, 2 or 3 years on an advisory basis on the compensation paid to the company's named executive officers, the proposal to do so every year has passed. The vote totals were for every year, 2,576,591; every 2 years, 9,558; every 3 years, 85,899; abstentions, 20,620; broker nonvotes, 945,034.
On the proposal to approve on an advisory basis, the actual compensation paid to the company's named executive officers, the proposal has passed. The vote totals were 2,562,179 votes for, 115,843 votes against, 14,646 abstentions, 945,034 broker nonvotes.
On the proposal to ratify the appointment of Grassi & Company, CPAs P.C. as the company's independent public accountants for the fiscal year ending December 31, 2026. The proposal has passed. The vote totals were 3,566,216 votes for, 45,290 votes against, 26,196 abstentions. I call for a motion that the vote certification of the inspectors of election be filed with the records of the corporation.
I move that the vote certification of the inspectors of election be filed with the records of the corporation.
And I second the motion.
All those in favor, say aye.
[Voting]
Aye
Aye
All opposed, say no.
[Voting]
The motion is carried. The complete voting results will be posted on our website. At this time, we'd like to have a discussion and question and answer. I will share my screen.
2. Question Answer
Can I ask a question?
Sure.
Can you tell us -- my name is Douglas Ruth. I'm from Lenox Financial Services. I'm a stock broker. Could you give us an update on what's happening with the pharmaceutical business? It seems like that business is moving in the right direction.
Sure. I will be happy to do that. I'm going to go through the presentation first because part of that will touch upon that, and then I can follow up with any additional questions that you might have, if that's okay.
Yes.
Okay. Great. Okay. Can everybody see my screen? Okay. So today's agenda, we want to talk about some of the key achievements that we've had throughout the year. We'll talk about the financial performance for fiscal year 2025. We'll talk about the financial performance for Q1 2026 and then some of our strategic goals as where we're headed.
So in terms of key achievements, we have expanded the market this year with signing a new distribution agreement with Azelis to expand the reach of our medical lubricants. We added a new product to our portfolio for the sexual wellness market. We initiated the project to expand formulary status for Renacidin, which has been very successful so far, and we're happy to see where that is going to go. And we signed a new agreement with Brenntag for a new territory in the personal care space.
In terms of financial performance, so fiscal year 2025, we did see a decrease in net sales from $12,181,971 to $10,545,468. We also saw some decreases in retained earnings and stockholders' equity, retained earnings shifting from $11,423,434 to $10,772,580 retained earnings and the stockholders' equity $11,882,866 to $11,232,012. And that decrease was mainly due to the reduction in cosmetic ingredient sales, along with a reduction in net income compared with 2024.
If we look at the breakdown of that market, you can -- I'm not sure what happened with my screen. But if you could see the breakdown for 2024, we had 17% in the medical lubricants, 44% in cosmetic ingredients and 39% in pharmaceuticals, where that shift then in 2025, you're seeing 20% in medical lubricants, cosmetic ingredients at 29% and 51% in pharmaceuticals. So there was a shift there. We're starting to see an increase in pharmaceuticals, which is part of our efforts that we are working on to continue to expand Renacidin.
Due to this market mix, pharmaceuticals do have a higher cost of sales, which does impact the earnings compared to cosmetic ingredients and medical lubricants. When we look at Q1 2026, we are seeing an increase. So we did see net sales increase in Q1 due to higher sales in pharmaceuticals and cosmetic ingredients sales started to rebound.
Retained earnings and stockholders' equity also rose slightly due to a combination of increased net income and decreased dividend payments compared to Q1 of 2025. So we're happy to see that Q1 is starting to rebound.
In terms of the breakdown, we're looking at the product mix. In Q1 2025, we're seeing medical lubricants at 25%, cosmetic ingredients at 28% and pharmaceuticals at 47%. And in Q1 2026, we're seeing medical lubricants at 20%, cosmetic ingredients, again, rebounding a bit to 30% and pharmaceuticals again increasing to 50%. So again, that does impact earnings because the cost of sales for pharmaceuticals are higher compared to cosmetic ingredients and medical lubricants.
That does kind of show that the increase in pharma activities that we're doing is starting to pay off where we're seeing those increases in those sales.
So in terms of strategic goals, what we're looking moving forward, we are asking all of our cosmetic ingredient distributors to have growth goals, and those goals are being monitored during our business review. So we are looking for them to increase sales and provide additional drivers for business, increased customer base, increased portfolio. So we are really looking to increase the business there in personal care.
For product expansion, as was mentioned, we have been expanding our resources for Renacidin and expanding the market there with a payer and health care practitioner outreach.
And with the payer outreach, we're starting to see some real traction there where that is allowing us to reduce the barrier for HCPs to prescribe Renacidin which allows more patients to have access to the product. So we're starting to see that shift.
It's looking like that's really starting to impact the way the product is received and patients are able to access the product, and we'll continue to work on that. We also want to make sure that the outreach is available so that doctors know that these products are -- have more formulary status and are able to prescribe them to patients without that barrier existing.
For product innovation, we have two new products that are launching later this year and early next year, one in skin care, one in hair care. The skin care product is a 24-hour hydration product and the benchmark against that is HA. So we're hoping that we can get some increased business with this product, which is a little bit different than the other products that we have.
And the hair care product is a natural ingredient, which is very popular now in personal care. A lot of customers are looking toward natural ingredients. And this is different for the hair care market where it typically doesn't have as many natural ingredients.
So we're looking forward to seeing some increased business with that product. Customer success, we are continuing to build the relationships with our customers. We participate in webinars, customer seminars, joint customer visits with our distributors, and we are able to get closer to the customer, understand their needs, get their feedback, which helps us to develop new products and to provide additional information so that they can be incorporated into finished formulations.
In terms of distributor partnerships, we continue to expand those relationships to better serve our customers. Again, we signed the distribution agreement with Azelis this year. We also signed distribution agreement with Brenntag for a new territory. So we are constantly looking to find ways to improve our distribution partnerships and serve our customers. And we also have growth initiatives that the company has created a growth committee for.
So these are for new opportunities, new ways to expand our business. They meet regularly and discuss different ideas and things that the company can pursue in terms of growth and making sure that we're constantly pursuing growth opportunities. I don't know if that answered some of your questions on the Renacidin, if there's additional information that you'd like to.
What has to happen in order to -- for the -- with the two pharmacy benefit managers in order to further increase the sales here?
So as -- I think we need to ensure that the healthcare providers are aware that the products have better formulary access, which is part of the next step in our initiative for Renacidin. So we are exploring ways in which we can have additional outreach to HCPs. So they're aware that formulary barrier has been removed in some cases, and they can now prescribe without having that as a barrier for patients to access the product.
Could you maybe simplify what -- so possibly a doctor recognizes that your drug might help? And what is the roadblock to the patient maybe being able to be given that drug? Maybe you can explain that.
Sure. I think the bigger barrier there is more about the insurance landscape. So if a doctor prescribes Renacidin and it isn't covered by the insurance carrier, then the patient may not be able to get the product. And by reducing that barrier, having it available on formulary gives doctors more incentive to then prescribe because they know the patient isn't going to come back to them and say, "Well, I can't get this product, what else can I do?
So I think that's where the limitation was existing in terms of a barrier. Now that barrier is starting to be removed. So as doctors know, okay, if it's -- there's more formulary status, there's less likely that the patient won't be able to get the product, and they'll be able to start that treatment.
Now why wouldn't the drug be -- the drug is known to help certain people, why wouldn't the drug be available?
It really depends on the payers and how they create their formularies. So that's part of the work that we're doing is to understand how to ensure that the payers that develop formularies understand the value of the drug.
Can I add something to that? Just real quick, just to make sure that there's no misunderstanding here. It's not that the product is not available. The product is available nationwide through multiple distributors. It's a question of whether the patient can afford it. If it's not on their formulary, they're not going to get reimbursed for it or it's not going to be covered. And it's -- for a lot of people, it's just too expensive. So it's not an availability issue. It's just an affordability issue.
And can you give us an idea of like how much it might cost?
I mean I personally don't know what the distributors resell it for. That's really up to them. I mean it's not a huge markup. But all I can tell you is that over the years, a lot of people have told us the people that don't have coverage for it is that it's just too expensive for them.
Well, is it like -- is it $100 for a treatment? Is it $200? Maybe just give us some perspective of how much it might be to help us understand.
Do you remember what their markup is on it?
Yes, it will vary by retail pharmacy as well because it gets sold into a retail pharmacy. So the pricing could be very different.
Well, what is the wholesale cost? So let's just say that they double the cost. So is it -- do you sell it to somebody for $100 and they resell it for $200...
What's our price per bottle on...
Andrea, do you know the wholesale acquisition cost for Renacidin?
Yes, $182.14.
For a box.
Yes.
Yes. So that's for 6 bottles.
Okay. And then what is -- what would be a normal -- how many bottles might a person need to be in a normal treatment cycle?
No, it's 30 bottles in a box...
Yes, 30 by 30 in a box. And it really depends on what the doctor is prescribing. So the volume varies by patient.
Well, would you need -- would one box take care of a person who has a problem, do you think?
Typically, there would be a box prescribed per month, maybe 2, depending on the units that the patient needs.
All right. So you need -- so 2 boxes and then how many months do you need to take the drug?
Well, most people that need the product are on it typically for the lifetime of the catheter that they have, which most of those people have indwelling catheters, which is permanently placed, but they're there.
So you need 2 boxes per month for the rest of your life possibly.
1 or 2 boxes.
Yes. It depends on -- of course, it depends on the patient and what they're...
A box and a half. I'm going to go with the box and a half for the rest of your life.
Okay. All right. Well, that gives us some perspective. Now we can understand. I mean that -- obviously, the distributor has the right to make some money. So if they double the cost, it's $360 for one box. So it's $540 a month for -- possibly for the drug. Okay. My second question was -- with the Brenntag going -- the possibility of going to France, I was wondering if you could explain to us how you chose France and what you think might happen there, how they chose France or maybe you chose France?
Yes. I mean, France is a big market for personal care. And when we're looking at that market, we know that it is shifting to a more natural space where in the past, maybe some of the synthetic ingredients were more popular. Now it's moving to more natural. We felt that Brenntag had the right positioning to access the customers in France for the natural products that we're looking to promote.
Do you think that in 2026 that you might be able to secure a customer for the sexual awareness products?
Yes. We do believe that we will have customer for sexual wellness in 2026.
Initially, you thought that there might be -- you had a prospect for 2025. Did that prospect perhaps shift from 2025 to 2026?
I believe that may have been that the project didn't move forward for the customer. So sometimes that happens where a customer has a project and then they were planning to launch and then it just gets delayed or the project gets put on hold. So -- but we do believe that there's a customer that we know of now that we will be purchasing and we should see those sales in 2026.
And how about the competitors? Are they having any success with their products for the sexual wellness, the natural products?
We really haven't seen a lot of competition in this space because it's a very -- it's a newer space. It's a niche space. And I think from what we've heard from our distributor, there's a lot of interest in the sexual wellness space. There's a lot of customers that are interested to get into this space. There are some regulatory hurdles that they have to consider. So it is a little bit more slow moving. But we really haven't heard of a lot of competition directly in that space as of right now.
Okay. I want to thank the company and the Board of Directors for hosting the meeting and then answering my questions.
Are there any other questions?
Yes, I have a question, Ken [indiscernible]. One of the headwinds that you mentioned in the past year was dealing with the various tariffs. I noticed in the news recently that companies are now starting to get refunds from the tariffs. I believe there's something like 330,000 importers that are requesting tariff refunds.
I was wondering what amount of money do you see Guardian getting back from these tariffs and these tariff refunds and when we might expect to receive that money?
Andrea, do you want to take that question in terms of tariffs?
Sure. So in terms of the tariffs, we -- United Guardian are not the importer of record for any products coming in. So we are not doing any refunds for tariffs because we didn't pay any direct tariffs as a result.
Okay. We were talking about Renacidin quite a bit. I noticed going back many years, it seems like about every 5 or 10 years or so, you run into a problem with your contract manufacturers. I was wondering what current backups you have if you were to run into a problem again or even if you have tried to produce this product on your own?
It's a very specialized process. And with an FDA approved drug, you can only have certain contract manufacturers that have to be approved. So it is a concern. It's always something that we have to be mindful of. We do work very closely with our contract manufacturer to make sure that things are running smoothly and that there are no issues that are on the horizon.
Unfortunately, sometimes there are things that come up that we can't foresee. And we've had some issues in the past there. But it's a very highly specialized type of process and not something that we have the capabilities to do in-house and would have to have that manufacturer approved by the FDA in order to have a secondary contract manufacturer.
Okay. Again, talking about Renacidin, it's been a product of yours for many, many years. Why has it been so difficult to try to get into international markets?
I think the main driver there is I think we needed to ensure that we had the success in the U.S. market to make sure that we had a very good understanding of how to take this forward. And I think that's getting additional sales here and having more interest in the product, I think that will help us move to some of the other markets that we're looking at and defining which markets are going to be the best ones for us to start our introduction into international spaces.
Glancing at the proxy statement, I noticed that we can see the bonuses that are received by top executives. What we see in this year's proxy under the heading of 2025 is that actually the bonus that was received last year?
Let me look at that. I believe so, right? Andrea, if you...
Yes
I believe so.
It would be year paid.
Yes. Paid in 2025.
Okay. So I believe according to the report, you just received your 2026 bonuses in April of this year for how you produced last year.
Yes
Can you give us an idea of did those bonuses increase, decrease or remain the same from the previous year?
They were reduced from the previous year.
Okay. Also in the proxy statement, we noticed that top executives have made a decision not to participate in the ownership of United Guardian. Can you give any philosophical reasons or financial reasons why you made that decision?
Ken, is that something you want to answer?
No. No, I would just say that No, we don't.
Ken is the one who is the shareholder. I'm sort of focusing on the other two or three.
No, I understand what the question is. It -- that's up to the individual officers and directors, what they -- where they want to put their investments. We don't tell people to buy stock or not buy stock in the company. It's really their own choice. I don't think it reflects on their attitude towards the company at all, but it's a very individual decision about where somebody puts their financial resources.
Okay. So you don't think it's a kind of lack of faith in the company?
I don't believe that's the case, no.
One final question. I think Mr. Globus might have the best insight into this. Of course, the company has been a public company for over 40 years now, something like that.
Longer than that. 1950s.
Okay. I thought it went public in 1980s.
That was a merger of the 2 companies that incorporated into the current company, United Guardian. Guardian Chemical Corporation was merged into United International Research, which was a public company formed in the 1950s. So that merger created United Guardian in the 1980s.
Okay. So my question is pretty basic. Companies basically go public for, I guess, two major reasons: one, to raise capital; and secondly, possibly to let corporate insiders get a chance to monetize their holdings. Neither of those reasons seem to apply to Guardian in its current format.
So I just asked the basic question, why has the company decided to remain a public company? Obviously, there's various expenses that occur for a public company, various issues with having to hold these meetings, which, of course, takes some of your time away from what you want to be doing. So Ken, maybe you're the best one to answer that question.
Well, I can just -- we have looked into it. There was one time many years ago that we were seriously looking at the possibility and met with some people and realized that the cost of doing it was just too great at that time. Even at the current stock price, it would mean taking on a lot of debt, which we weren't willing to do. So we just felt that there was enough of a benefit. Yes, there was certainly a cost, time and money in being a public company.
But I also feel that we do a lot ourselves. I think we keep those costs to a minimum compared to a lot of other companies. I think our expenses to remain public are relatively low compared to many other companies. And again, I think the primary reason really was just the cost of doing it.
So you would sort of agree that being public doesn't really give you the benefits of most public companies.
I'm sorry, could you repeat that?
Well, just repeating what I had said before, the goal of going -- the purpose for going public doesn't seem to apply to Guardian in its current format.
I'm not sure I can really answer that. It's not like we have really an option -- a practical option now to do anything to change that, whether we should have been a public company or not, you have to go back 60 years to discuss that issue. But it is what it is right now. And I think a lot of people are satisfied. Obviously, we'd like more. We'd like to grow the sales as our stockholders would like us to do. But our yield is still pretty good compared to what you can get right now in the banks.
I think we're somewhere in the 7%, 6%-7% rate right now. And obviously, our goal is to increase sales and increase that dividend. So yes, we're very small for a public company. But I think we've been pretty successful, and we plan to grow that more significantly in the future. So there's not really much I can see doing about it right now. Again, it's just -- there's really not any motivation on the part of the company right now to incur the kind of debt that would be involved in going private at this point.
Are there any other questions we can answer?
No. I move that the meeting be adjourned.
I second the motion.
All those in favor, say aye.
[Voting]
Aye.
Aye
All those opposed, say no.
[Voting]
The motion is carried and the meeting is adjourned. Thank you very much for attending the Annual Meeting for United Guardian.
Thanks, Donna.
Thank you.
Thank you.
Financial data from United-Guardian, Inc.
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Jun '26 |
+/-
%
|
||
| Revenue | 11 11 |
3%
3%
100%
|
|
| - Direct Costs | 5.95 5.95 |
17%
17%
53%
|
|
| Gross Profit | 5.26 5.26 |
9%
9%
47%
|
|
| - Selling and Administrative Expenses | - - |
-
-
|
|
| - Research and Development Expense | 0.48 0.48 |
4%
4%
4%
|
|
| EBITDA | 2.45 2.45 |
16%
16%
22%
|
|
| - Depreciation and Amortization | 0.12 0.12 |
20%
20%
1%
|
|
| EBIT (Operating Income) EBIT | 2.33 2.33 |
17%
17%
21%
|
|
| Net Profit | 2.47 2.47 |
4%
4%
22%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about United-Guardian, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
United-Guardian, Inc. Stock News
Company Profile
United-Guardian, Inc. develops and manufactures pharmaceuticals, cosmetic ingredients, personal and health care products and medical devices. The firm conducts research and product development related to the development of new and unique cosmetic and personal care products. The company was founded by Alfred R. Globus in 1942 and is headquartered in Hauppauge, NY.
StocksGuide Premium
| Head office | United States |
| CEO | Beatriz Blanco |
| Employees | 24 |
| Founded | 1942 |
| Website | u-g.com |
